BioCangen

BioCangen is a clinical-stage biopharmaceutical company focused on the discovery and development of novel epigenetic therapies for cancer treatment. Headquartered in Rockville, Maryland, the company specializes in small molecule inhibitors that target histone deacetylases (HDACs) to regulate gene expression and induce tumor cell death. BioCangen's lead candidate, CGB-011, is a potent HDAC inhibitor being evaluated for its efficacy in treating various solid tumors and hematological malignancies. The company leverages its expertise in medicinal chemistry to develop therapies with improved selectivity and reduced toxicity compared to existing treatments. BioCangen aims to address significant unmet needs in oncology through its innovative pipeline of epigenetic modulators.